The estimated Net Worth of John Kenneweg is at least $34.5 Mille dollars as of 12 April 2022. John Kenneweg owns over 9,880 units of 908 Devices stock worth over $34,481 and over the last 3 years John sold MASS stock worth over $0.
John has made over 10 trades of the 908 Devices stock since 2021, according to the Form 4 filled with the SEC. Most recently John exercised 9,880 units of MASS stock worth $3,458 on 12 April 2022.
The largest trade John's ever made was exercising 19,881 units of 908 Devices stock on 18 March 2022 worth over $6,958. On average, John trades about 8,323 units every 25 days since 2021. As of 12 April 2022 John still owns at least 9,880 units of 908 Devices stock.
You can see the complete history of John Kenneweg stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON, MA, 02210.
Over the last 4 years, insiders at 908 Devices have traded over $16,182,689 worth of 908 Devices stock and bought 826,585 units worth $15,798,345 . The most active insiders traders include Keith Crandell, Kevin J. Knopp e E Kevin Hrusovsky. On average, 908 Devices executives and independent directors trade stock every 10 days with the average trade being worth of $64,663. The most recent stock trade was executed by Christopher D. Brown on 7 August 2024, trading 6,328 units of MASS stock currently worth $9,998.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
908 Devices executives and other stock owners filed with the SEC include: